Tovorafenib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Craniopharyngioma, Child
Conditions
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Trial Timeline
Sep 12, 2022 → Mar 1, 2028
NCT ID
NCT05465174About Tovorafenib
Tovorafenib is a phase 2 stage product being developed by Day One Biopharmaceuticals for Craniopharyngioma, Child. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05465174. Target conditions include Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05760586 | Pre-clinical | Completed |
| NCT05465174 | Phase 2 | Recruiting |
| NCT04985604 | Phase 2 | Terminated |
| NCT04775485 | Phase 2 | Recruiting |
Competing Products
2 competing products in Craniopharyngioma, Child
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Oral dabrafenib and trametinib | Novartis | Phase 2 | 52 |
| peginterferon alfa-2b | Brain Biotech | Phase 2 | 44 |